New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 12, 2014
09:11 EDTRAREUltragenyx reports Q1 EPS (85c), consensus (37c)
Total operating expenses for Q1 were $10.3M compared with $6.7M for the same period in 2013. The increase in total operating expenses is due to the expansion and advancement of Ultragenyx's clinical development pipeline, including the initiation of clinical studies for triheptanoin and recombinant human beta-glucuronidase, as well as increased headcount.
News For RARE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 15, 2014
09:04 EDTRAREUltragenyx initiates Phase 3 study of rhGUS, UX003
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use